Date: 2014-05-19
Type of information: Commercialisation agreement
Compound: C-Cathez®
Company: Cardio3 BioSciences (Belgium) Viromed (South Korea)
Therapeutic area: Cardiovascular diseases
Type agreement: commercialisation
Action mechanism: C-Cathez® is C3BS’ steerable percutaneous catheter. With its nitinol-based curved needle and side holes, this new generation of percutaneous injection catheter for myocardial delivery has been designed and developed to elevate the standard of care to clinicians and patients by focusing on three key features: local drug concentration, safety, and ease of use. With C-Cathez®, Cardio3 BioSciences provides the clinician with a catheter which can be safely steered to reach target sites within the heart left ventricle. C-Cathez® permits stable contact with the beating myocardium without generating additional tissue trauma and diffuses the therapeutic agent over a bigger target area to obtain both a higher concentration and a wider tissue exposure.
Disease: ischemic cardiovascular diseases
Details: * On May 19, 2014, Cardio3 BioSciences, a leader in the discovery and development of advanced regenerative therapies for heart disease, announced that it has entered into a trade agreement with ViroMed for the use of Cardio3 BioSciences’ catheter C-Cathez® in the development of ViroMed’s VM202-CAD product in Korea. VM202-CAD is ViroMed\'s gene therapy-based that expresses HGF for the treatment of ischemic cardiovascular diseases via therapeutic angiogenesis. A Phase I clinical study for VM202-CAD has beencompleted in Korea and a phase II clinical study is planned for Q4 2014. This is Cardio3 BioSciences\' first commercial agreement to supply C-Cathez®.
Financial terms: Financial terms were not disclosed.
Latest news:
